• LinkedIn Social Icon
  • Black Facebook Icon
  • Black Twitter Icon

Saudi Immunotherapy Symposium 2018

24 November 2018

Movenpick Hotel, Riyadh, Saudi Arabia

Scientific Committee

Nagwa Ibrahim, Pharm D, PhD

Chair, SIS 2018

Clinical Pharmacist Specialist, Oncology

Prince Sultan Military Medical City

Riyadh, Saudi Arabia

Eman Al Obary, MSc, BCPS

Clinical Pharmacist, Specialist, Internal Medicine - GI/Hepatology

Prince Sultan Military Medical City

Riyadh, Saudi Arabia

Bedor Al-Omari, BSc. Pharm, SSC.PhP, SSCIMP

Clinical Pharmacist Specialist, Internal Medicine & Rheumatology

Department of Pharmaceutical Services

Prince Sultan Military Medical City

Riyadh, Saudi Arabia

Faculty

Hanan Al Rayes , MD

Consultant Rheumatology

President Of Saudi Society For Rheumatology

Deputy Director of Medicine Department

Prince Sultan Military Medical Studies

Nagwa Ibrahim, Pharm D, PhD

Chair, SIS 2018

Clinical Pharmacist Specialist, Oncology

Prince Sultan Military Medical City

Riyadh, Saudi Arabia

Eman Al Obary, MSc, BCPS

Clinical Pharmacist, Specialist, Internal Medicine - GI/Hepatology

Prince Sultan Military Medical City

Riyadh, Saudi Arabia

Bedor Al-Omari, BSc. Pharm, SSC.PhP, SSCIMP

Clinical Pharmacist Specialist, Internal Medicine & Rheumatology

Department of Pharmaceutical Services

Prince Sultan Military Medical City

Riyadh, Saudi Arabia

Ashraf Al Alwan, PhD

Director for Clinical Services

Consultant Clinical Pharmacist

Department of Pharmaceutical Services

Prince Sultan Military Medical City

Riyadh, Saudi Arabia

Program 

The immune system overview
Role of immunotherapy in management of different types of cancer
Advances in management of metastatic NSCLC
Management of immunotherapy side effects 
Optimal treatment strategies in rheumatoid arithritis
Role of immunotherapy in management of inflammatory bowl diseases
Updates in management of psoriasis
Therapeutic drug monitoring of immunotherapy
Updates on therapeutic targets in the treatment of spondyloarthropathies
Cost effectiveness of immunotherapy
Biosimilars in immunotherapy
Challenges in immunotherapy pricing and inventory control??
Clinical cases
 
Current and future strategies in balancing costs while improving outcomes
End of the program